MX2016000043A - Polisacarido de acido poligulonico sulfatado o sal farmaceutica del mismo, metodo de preparacion del mismo y su uso. - Google Patents
Polisacarido de acido poligulonico sulfatado o sal farmaceutica del mismo, metodo de preparacion del mismo y su uso.Info
- Publication number
- MX2016000043A MX2016000043A MX2016000043A MX2016000043A MX2016000043A MX 2016000043 A MX2016000043 A MX 2016000043A MX 2016000043 A MX2016000043 A MX 2016000043A MX 2016000043 A MX2016000043 A MX 2016000043A MX 2016000043 A MX2016000043 A MX 2016000043A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- same
- preparation
- polygulonic acid
- sulfated
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 4
- 102000007469 Actins Human genes 0.000 abstract 2
- 108010085238 Actins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 239000003966 growth inhibitor Substances 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 102100024025 Heparanase Human genes 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000002257 antimetastatic agent Substances 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 108010037536 heparanase Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La presente invención se relaciona con un polisacárido del ácido poligulónico sulfatado o una sal farmacéuticamente aceptable del mismo, método de preparación del mismo y su uso en la preparación de inhibidores del crecimiento y/o metástasis de cáncer. El polisacárido del ácido poligulónico sulfatado o una sal farmacéuticamente aceptable del mismo pueden usarse para la preparación de uno o más inhibidores del crecimiento de cáncer, inhibidores de metástasis de cáncer, inhibidores de angiogénesis, inhibidores de heparanasa, inhibidores de la enzima C-Met, inhibidores de la polimerización microtubular, inhibidores de la actividad del factor de despolimerización de actina e inhibidores de la agregación de actina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310275323.7A CN104277130A (zh) | 2013-07-02 | 2013-07-02 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
| PCT/CN2014/081472 WO2015000411A1 (zh) | 2013-07-02 | 2014-07-02 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000043A true MX2016000043A (es) | 2016-05-31 |
| MX373099B MX373099B (es) | 2020-03-31 |
Family
ID=52143111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000043A MX373099B (es) | 2013-07-02 | 2014-07-02 | Polisacárido de ácido poligulónico sulfatado o sal farmacéutica del mismo, método de preparación del mismo y su uso. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10058566B2 (es) |
| EP (1) | EP3018147B1 (es) |
| JP (2) | JP6757249B2 (es) |
| KR (1) | KR102258569B1 (es) |
| CN (2) | CN104277130A (es) |
| AU (1) | AU2014286711B2 (es) |
| BR (1) | BR112015032849B1 (es) |
| CA (1) | CA2916749C (es) |
| DK (1) | DK3018147T3 (es) |
| EA (1) | EA028655B1 (es) |
| ES (1) | ES2674976T3 (es) |
| HU (1) | HUE038981T2 (es) |
| MX (1) | MX373099B (es) |
| PL (1) | PL3018147T3 (es) |
| PT (1) | PT3018147T (es) |
| SG (1) | SG11201510717SA (es) |
| TR (1) | TR201809674T4 (es) |
| WO (1) | WO2015000411A1 (es) |
| ZA (1) | ZA201509353B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104277130A (zh) * | 2013-07-02 | 2015-01-14 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
| CN107904240A (zh) * | 2017-12-04 | 2018-04-13 | 辽东学院 | 一种抗肝癌细胞转移的抑制剂组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3228231A1 (de) | 1982-07-28 | 1984-02-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung |
| JPH0625304A (ja) | 1992-07-06 | 1994-02-01 | Higeta Shoyu Co Ltd | ガラクトサミン重合体硫酸化物及び該物質を 含有する抗ウイルス剤 |
| CN1132209A (zh) | 1995-03-27 | 1996-10-02 | 青岛海洋大学 | 一种新药多聚甘露糖醛酸硫酸盐 |
| GB2317182B (en) | 1996-09-11 | 2000-11-01 | Johnson & Johnson Medical | Sulfated polysaccharides and uses thereof in medical treatment |
| CN1473836A (zh) | 2003-08-04 | 2004-02-11 | 中国海洋大学 | 还原端1位为羧基的古罗糖醛酸寡糖及其衍生物 |
| CN1213071C (zh) * | 2003-11-25 | 2005-08-03 | 中国海洋大学 | 一种古糖酯及其制备方法和应用 |
| JP4897310B2 (ja) | 2006-02-28 | 2012-03-14 | 理研食品株式会社 | Ｌ−グルロン酸金属塩又はｄ−マンヌロン酸金属塩の製造方法 |
| JP2008027767A (ja) | 2006-07-21 | 2008-02-07 | Aomori Prefecture | 固体高分子電解質膜及び燃料電池 |
| CN101691410B (zh) * | 2009-09-18 | 2011-12-28 | 中国海洋大学 | 一种具有防治胰岛素抵抗作用的海洋寡糖铬配合物 |
| RU2553348C2 (ru) | 2010-03-10 | 2015-06-10 | Айновобайолоджик, Инк. | Продукт, содержащий глюкоманнан, ксантановую камедь и альгинат для лечения метаболических нарушений |
| CN102743409B (zh) | 2012-06-18 | 2013-11-20 | 中国海洋大学 | 聚甘露糖醛酸丙酯硫酸盐在制备抗甲型h1n1流感病毒药物中的应用 |
| CN104277130A (zh) * | 2013-07-02 | 2015-01-14 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
-
2013
- 2013-07-02 CN CN201310275323.7A patent/CN104277130A/zh active Pending
-
2014
- 2014-07-02 CN CN201480038171.1A patent/CN105358582B/zh not_active Expired - Fee Related
- 2014-07-02 KR KR1020167002769A patent/KR102258569B1/ko not_active Expired - Fee Related
- 2014-07-02 DK DK14819337.8T patent/DK3018147T3/en active
- 2014-07-02 US US14/901,297 patent/US10058566B2/en not_active Expired - Fee Related
- 2014-07-02 WO PCT/CN2014/081472 patent/WO2015000411A1/zh not_active Ceased
- 2014-07-02 BR BR112015032849-0A patent/BR112015032849B1/pt not_active IP Right Cessation
- 2014-07-02 HU HUE14819337A patent/HUE038981T2/hu unknown
- 2014-07-02 MX MX2016000043A patent/MX373099B/es active IP Right Grant
- 2014-07-02 ES ES14819337.8T patent/ES2674976T3/es active Active
- 2014-07-02 SG SG11201510717SA patent/SG11201510717SA/en unknown
- 2014-07-02 AU AU2014286711A patent/AU2014286711B2/en not_active Ceased
- 2014-07-02 JP JP2016522246A patent/JP6757249B2/ja not_active Expired - Fee Related
- 2014-07-02 EP EP14819337.8A patent/EP3018147B1/en not_active Not-in-force
- 2014-07-02 PL PL14819337T patent/PL3018147T3/pl unknown
- 2014-07-02 CA CA2916749A patent/CA2916749C/en not_active Expired - Fee Related
- 2014-07-02 EA EA201690123A patent/EA028655B1/ru unknown
- 2014-07-02 TR TR2018/09674T patent/TR201809674T4/tr unknown
- 2014-07-02 PT PT148193378T patent/PT3018147T/pt unknown
-
2015
- 2015-12-23 ZA ZA2015/09353A patent/ZA201509353B/en unknown
-
2019
- 2019-02-22 JP JP2019030255A patent/JP6772318B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA028655B1 (ru) | 2017-12-29 |
| AU2014286711A1 (en) | 2016-02-04 |
| EA201690123A1 (ru) | 2016-07-29 |
| CA2916749C (en) | 2021-03-09 |
| CA2916749A1 (en) | 2015-01-08 |
| ES2674976T3 (es) | 2018-07-05 |
| CN104277130A (zh) | 2015-01-14 |
| CN105358582B (zh) | 2018-09-21 |
| MX373099B (es) | 2020-03-31 |
| JP6772318B2 (ja) | 2020-10-21 |
| JP2016523301A (ja) | 2016-08-08 |
| US10058566B2 (en) | 2018-08-28 |
| HUE038981T2 (hu) | 2018-12-28 |
| BR112015032849B1 (pt) | 2021-09-14 |
| EP3018147B1 (en) | 2018-05-23 |
| SG11201510717SA (en) | 2016-01-28 |
| KR20160029817A (ko) | 2016-03-15 |
| TR201809674T4 (tr) | 2018-07-23 |
| JP6757249B2 (ja) | 2020-09-16 |
| KR102258569B1 (ko) | 2021-05-28 |
| ZA201509353B (en) | 2017-08-30 |
| AU2014286711B2 (en) | 2018-05-10 |
| HK1220984A1 (zh) | 2017-05-19 |
| US20160367591A1 (en) | 2016-12-22 |
| JP2019090056A (ja) | 2019-06-13 |
| EP3018147A1 (en) | 2016-05-11 |
| PT3018147T (pt) | 2018-07-17 |
| WO2015000411A1 (zh) | 2015-01-08 |
| PL3018147T3 (pl) | 2018-10-31 |
| EP3018147A4 (en) | 2017-04-05 |
| DK3018147T3 (en) | 2018-07-23 |
| CN105358582A (zh) | 2016-02-24 |
| BR112015032849A2 (pt) | 2020-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| PL3003330T4 (pl) | Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania | |
| EA201690780A1 (ru) | Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство | |
| ECSP15004752A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| SI3021869T1 (sl) | Postopki zdravljenja raka z uporabo antagonistov in inhibitorjev TIGIT, ki se vežejo na os PD-1 | |
| NZ760790A (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| DK3041946T3 (da) | Fermentative production of oligosaccharides | |
| MX378792B (es) | Células hospederas modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados. | |
| DOP2012000252A (es) | Procedimientos para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico | |
| DOP2013000248A (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinocetan (flfiri) | |
| IL243627A0 (en) | High potency pancreatin pharmaceutical compositions | |
| LT3003268T (lt) | Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api) | |
| BR112016023498A2 (pt) | composições para higiene bucal | |
| CL2016000143A1 (es) | Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel | |
| BR112017018073A2 (pt) | agentes de escoramento de poliolefina de ultra alto peso molecular | |
| IN2013MU00711A (es) | ||
| WO2014153495A3 (en) | Novel stat3 inhibitors | |
| AR100634A1 (es) | Fluidos de tratamiento para reducir el daño en formaciones subterráneas | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
| PE20151206A1 (es) | Polipeptidos del factor vii de accion corta | |
| EA201890212A1 (ru) | Новое применение сульфата декстрана | |
| MX390436B (es) | Sistemas y metodos de hidratacion. | |
| MX2015016603A (es) | Composiciones de corticosteroides. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |